Abdera Therapeutics’ Radiopharmaceutical ABD-147 Shows Early Promise in SCLC and LCNEC

Abdera Therapeutics has released encouraging Phase Ia data for ABD-147, its DLL3-targeting radiopharmaceutical biologic, in patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). ABD-147 delivers the alpha-emitting isotope Actinium-225 directly to DLL3-expressing tumours, found in roughly 85% of SCLC cases.

The first cohort of six patients demonstrated favourable pharmacokinetics, showing strong tumour uptake and rapid clearance from blood and organs, with projected radiation doses staying within organ safety limits. CT imaging confirmed selective lesion targeting. The therapy was well tolerated, with no infusion-related reactions, dose modifications, or dose-limiting toxicities reported.

Early signs of anti-tumour activity were observed, including disease stabilisation in multiple patients, one maintaining stability for over four months. These results supported continued dose escalation. ABD-147 has received FDA fast track designation for extensive-stage SCLC after chemotherapy and orphan drug status for neuroendocrine carcinoma.

16-09-2025